Combination Approaches in PD-L1–Positive Metastatic Triple Negative Breast Cancer

Welcome to the Oncology Brothers podcast! In this episode, we dived into the evolving frontline treatment landscape for triple-negative breast cancer (TNBC).Listen us on:Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966Follow us on social media:•⁠ ⁠X/Twitter: https://twitter.com/oncbrothers•⁠ ⁠Instagram: https://www.instagram.com/oncbrothers•⁠ Website: https://oncbrothers.com/Join us as we welcomed Dr. Sherene Loi, a leading breast medical oncologist from Australia, to discuss the challenges of treating TNBC and the exciting new treatment options available. We explored the significance of PD-L1 scoring in metastatic TNBC, the implications of recent trials like ASCENT-04, and the potential of antibody-drug conjugates (ADCs) such as sacituzumab govitecan and datopotamab deruxtecan.Key topics included:• The role of PD-L1 positivity in treatment decisions• Insights from the ASCENT-04 trial and its findings• Common side effects associated with sacituzumab and strategies for management• The future of immunotherapy and ADCs in TNBC treatmentWhether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode is packed with valuable information and clinical pearls. Don't forget to subscribe for more insightful discussions on cancer treatment!#TNBC, #PDL1positive, #ASCENT04, #Immunotherapy, #OncBrothers